VivoSeq
Other

Knee Injury

9

Pipeline Programs

2

Active Trials

4

Companies Involved

Knee Injury is an early-stage landscape with 9 programs across 4 companies. The most active players are Pfizer, GSK, Fresenius Kabi Oncology Ltd.. 2 therapies are approved with 2 more in late-stage development.

Pipeline Metrics

Competitive Density

36/100

Pipeline Velocity

11/100

Mech. Concentration

14/100

Completion Rate

83/100

Attrition Rate

13/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

Modality Breakdown

90%

Small molecule

9 of 10 classified programs — the dominant modality here.

10%ALL OTHERSCell therapy110%

Small molecule leads; the ring shows all 10 classified programs, each share of the total. Modality classified for 100% of 10 pipeline programs.

Trial Status

8

clinical trials

Completed5 · 63%
Terminated1 · 13%
Recruiting1 · 13%
Not yet recruiting1 · 13%

Trial Activity

8 trials

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)